Repository logo
 
Publication

Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: a Pooled Analysis

2021Journal article Open access
Simple item page
dc.contributor.authorWissel, J
dc.contributor.authorCamões-Barbosa, A
dc.contributor.authorComes, G
dc.contributor.authorAlthaus, M
dc.contributor.authorScheschonka, A
dc.contributor.authorSimpson, D
dc.date.accessioned2022-01-19T15:04:39Z
dc.date.available2022-01-19T15:04:39Z
dc.date.issued2021
dc.description.abstractSome studies have shown that incobotulinumtoxinA reduces spasticity-associated pain, but further evidence is needed. This exploratory analysis pooled pain-relief data from six Phase 2 or 3 studies of incobotulinumtoxinA (four placebo-controlled studies) for treating upper limb spasticity in adults. Spasticity-associated pain was assessed at baseline and 4 weeks post incobotulinumtoxinA injection using the disability assessment scale (DAS) for pain. Only data for patients with pain at baseline were analysed. Overall, 544 (incobotulinumtoxinA, N = 415; placebo, N = 129) of 937 patients (58.1%) experienced pain at baseline. At Week 4, a significantly greater proportion of incobotulinumtoxinA- (52.1%) than placebo-treated patients (28.7%; Chi-square p < 0.0001) showed a response (≥1-point improvement in DAS pain score). In logistic regression analysis, incobotulinumtoxinA-treated patients were 2.6 times more likely to achieve this endpoint than placebo-treated patients. A significant difference between incobotulinumtoxinA and placebo was observed regardless of baseline pain severity. Additionally, 27.1% of incobotulinumtoxinA- versus 12.4% of placebo-treated patients reported complete pain relief at Week 4 (p = 0.0006). Pain relief increased with multiple injection cycles. To achieve patient-centred care, pain relief may be considered a treatment goal in adults with spasticity-associated pain regardless of pain severity. This study contributes to understanding the benefits of incobotulinumtoxinA in treating limb spasticity-associated pain.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationToxins (Basel). 2021 Dec 11;13(12):887.pt_PT
dc.identifier.doi10.3390/toxins13120887.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3957
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.subjectCHLC MFRpt_PT
dc.subjectAdolescentpt_PT
dc.subjectAgedpt_PT
dc.subjectAdultpt_PT
dc.subjectAged, 80 and overpt_PT
dc.subjectMalept_PT
dc.subjectFemale
dc.subjectHumans
dc.subjectBotulinum Toxins, Type A / therapeutic use*
dc.subjectMiddle Aged
dc.subjectMuscle Spasticity / drug therapy*
dc.subjectMyalgia / drug therapy*
dc.subjectNeuromuscular Agents / therapeutic use*
dc.subjectYoung Adult
dc.subjectTreatment Outcome
dc.titlePain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: a Pooled Analysispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage887pt_PT
oaire.citation.titleToxinspt_PT
oaire.citation.volume13pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Toxins 2021.pdf
Size:
2.34 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

MFR - Artigos